ClinicalTrials.gg
CompletedNCT00823862Updated Apr 16, 2019

Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

A Phase 1 interventional study of SD-101 and ribavirin in Chronic Hepatitis C, sponsored by Dynavax Technologies Corporation. Completed at 5 sites in Poland. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2019-04-16.

Sponsored by Dynavax Technologies Corporation (part of Sanofi) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 49 studies in Hepatitis C, Chronic with a site in Poland — none open to participants now, 1 under way, 1 of them phase 3. Hepatitis C, Chronic · Poland.

Enrollment
40th of 41
34 · median 290
Started
2008
with 3 others
Phase 1
2 of 49
none open now
Registered
13th of 49
by date

Among the 49 studies in Hepatitis C, Chronic with a site in Poland, this one is the 40th largest by enrollment of the 41 interventional ones that give a count, is one of 4 that started in 2008, is one of 2 in phase 1, and was the 13th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 49 studies in Hepatitis C, Chronic with a site in Poland is open now. The open studies under Hepatitis C, Chronic, anywhere →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 49 studies in Hepatitis C, Chronic with a site in Poland as a file.
02

Study summary

To determine safety, tolerability, and preliminary efficacy of escalating doses of SD-101 alone and SD-101 plus ribavirin in subjects with chronic hepatitis C and no prior therapy.

03

Conditions studied

  • Chronic Hepatitis C

Browse trials for

Keywords

  • HCV
  • Immunostimulatory sequence (ISS)
  • TLR9 (toll-like receptor 9)
  • interferon (IFN)
  • ribavirin
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed, written,
  • Male or female subjects, 18 to 55 years of age.
  • Subject must have chronic infection , genotype 1.
  • Serum HCV-RNA concentrations 100,000 IU/mL to 10,000,000 IU/mL
  • No prior treatment for HCV.
  • Must be negative for (HBV) and (HIV).
  • Must be willing to use dual method of (i.e., barrier and spermicide; birth control pills and barrier) during the study.
  • No known to study medication or to drugs chemically related to the study.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with IFN-based therapies and/or anti-viral therapies.
  • Women with ongoing pregnancy or breast feeding and male partners of women who are pregnant.
  • Reduced kidney function.
  • Presence of concomitant liver diseases
  • Signs or symptoms of hepatocellular carcinoma.
  • Thyroid disease currently poorly controlled on prescribed medications.
  • History of hemoglobinopathy.
  • Evidence of severe retinopathy.
  • Other serious medical conditions, including , cancer (excluding non-melanoma skin cancer), or evidence of drug or alcohol abuse.
  • Subjects with documented or presumed coronary artery disease, pulmonary disease, or cerebrovascular disease
  • acute or chronic illnesses.
  • History of severe psychiatric disease, especially depression, characterized by a suicide attempt, hospitalization for psychiatric disease, or a period of disability as a result of psychiatric disease.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Investigator)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Active (SD-101)

    SD-101 in cohorts of escalating doses

    Drug: SD-101 · Drug: ribavirin

Interventions

  • DrugSD-101

    Intramuscular (IM)

    Also known as: CpG Class C Immunostimulatory Sequence (ISS), TLR9 Agonist

  • oral, 2 times per day, for 2 months

06

What researchers measure

Primary outcomes

  1. Adverse event timing, duration, and severity.

    Time frame: Between doses and up to 3 months after last dose

Secondary outcomes

  1. Biomarker analysis of blood sample

    Time frame: pre and 24 hour post dose

  2. Viral load in blood sample

    Time frame: each visit

07

Study locations

5 sites
  • Klinika Chorób Zakaźnych i Hepatologii Collegium Medicum Uniwersytet Mikołaja Kopernika
    Bydgoszcz, 85 - 030, Poland
  • Katedra i Klinika Chorób Zakaźnych Uniwersytet Medyczny w Lublinie
    Lublin, 20-089, Poland
  • Wojewódzki Szpital Zakaźny - Klinika Hepatologii i Nabytych Niedoborów Immunologicznych
    Warszawa, 01-201, Poland
  • Wojewódzki Szpital Zakaźny
    Warszawa, 01-201, Poland
  • EMC Instytut Medyczny S.A. Szpital Specjalistyczny z Przychodnią "EuroMediCare"
    Wrocław, 144-148, Poland
08

References and documents

Individual participant data

Plan to share: Undecided — 3/2017 no change to status in this Phase 1 study

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Dec 2009 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2009
First posted
Jan 16, 2009
Start
Oct 2008
Primary completionActual
Dec 2009
CompletionActual
Feb 2010
Last update
Apr 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00823862
Collaborators
Synteract, Inc., PPD DEVELOPMENT, LP
Responsible party
Sponsor
First posted
Jan 16, 2009
Start date
Oct 2008
Primary completion
Dec 2009
Completion
Feb 2010
Last update
Apr 16, 2019

Study contacts

Janusz Cianciara, MD
principal investigator · Warszawski Uniwersytet Medyczny

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nelitolimod

Start the discussion